# Adocia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adocia

- Industry: Biotechnology
- Headquarters: Lyon, France
- Website: www.adocia.com
- Total disclosed funding: $37M
- Latest round: Series B (Jan 27, 2010)
- Investors on record: 9

## About

Adocia is a biotechnology company dedicated to developing innovative treatments for diabetes and obesity, focusing on advanced insulin formulations and metabolic hormones to enhance patient care.Founded in 2005 and headquartered in Lyon, France, Adocia specializes in biopharmaceutical innovations for diabetes management and obesity. The company, founded by Olivier Soula, has undergone significant developments, including its IPO in March 2012, to expand its research and commercialization efforts. Olivier Soula leads the company as CEO, building upon his extensive experience in biotechnology.Adocia specializes in the development of innovative treatments primarily for diabetes and obesity, focusing on the formulation of advanced insulins and metabolic hormones. Their core product offerings include proprietary formulations that enhance the efficacy and usability of already-approved peptides and proteins, as well as immunoprotective scaffolds designed for cell therapies. These products are intended to improve glycemic control and weight management for patients suffering from type 1 and type 2 diabetes, alongside obesity-related metabolic issues. Adocia's products target pharmaceutical companies and healthcare providers in various global markets, including Europe and North America, who seek to license these innovative solutions for manufacturing and distribution.In the most recent year of 2022, Adocia reported a revenue of EUR 12,062,836, along with an EBITDA of EUR -1,266,666.3. The company's revenue generation is primarily through strategic partnerships and licensing agreements following successful human trial validations of their products, allowing pharmaceutical firms to commercialize their proprietary formulations.Adocia's strategy for future growth includes the development and launch of new products aimed at enhancing treatment options for diabetes and obesity. The company plans to further expand its market reach in Europe and North America within the next few years. The recent funding of EUR 14.000 mn raised during the Series B round will support these initiatives, focusing on product development and scaling operations.

## Funding rounds

- Series B, Jan 27, 2010, $20M — Idinvest Partners, CDC Enterprises, SGAM Private Equity, Bioam Gestion, Smalt Capital, Relyens
- Series A, Dec 21, 2007, $18M — Idinvest Partners, Eiffel Investment Group, Eurazeo, Bioam Gestion, Smalt Capital, Amundi

## Investors

- Idinvest Partners (https://capitalatlas.ai/funds/idinvest-partners) — Series A, Series B
- Eiffel Investment Group (https://capitalatlas.ai/funds/eiffel-investment-group) — Series A
- Eurazeo (https://capitalatlas.ai/funds/eurazeo) — Series A
- Bioam Gestion (https://capitalatlas.ai/funds/bioam-gestion) — Series A, Series B
- Smalt Capital (https://capitalatlas.ai/funds/smalt-capital) — Series A, Series B
- Amundi (https://capitalatlas.ai/funds/amundi) — Series A
- CDC Enterprises (https://capitalatlas.ai/funds/cdc-enterprises) — Series B
- SGAM Private Equity (https://capitalatlas.ai/funds/sgam-private-equity) — Series B
- Relyens — Series B